Publications

Peer Reviewed Publications

Book Chapters
Huang, Y. and Mahley RW. (1999) Apolipoprotein E and human disease. In Plasma Lipids and Their Role in Diseases. Editor, Philip J. Barter. p257–284.

Mahley, RW., and Huang, Y. (2003) Apolipoprotein E: structure and function in lipid metabolism and neurobiology. In The Molecular and Genetic Basis of Neurological Disease. Editors: Rosenberg, R.N., Prusiner, S.B., DiMauro, S., and Barchi, R.L., Nestler, E.J., Butterworth Heinemann, Newton, MA. p565–573.

Huang, Y. (2003) Transgenic and gene-targeted mouse models in hypoxic pulmonary hypertension research. In Hypoxic Pulmonary Vasoconstriction: Cellular and Molecular Mechanisms. Editor: Jason XJ. Yuan. p559–568.

Review Articles Published in Journals
von Eckardstein, A., Huang, Y., and Assmann, G. (1994) Physiological role and clinical relevance of high density lipoprotein subclasses. Curr. Opin. Lipidol. 5:404–416.

Assmann, G., Schulte, H., von Eckardstein, A., and Huang, Y. (1996) High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implication for reverse cholesterol transport. Atherosclerosis 124 (Suppl.):S11–S20.

von Eckardstein, A., Huang, Y., and Assmann, G. (1996) Uptake, transfer, and esterification of cell-derived cholesterol in plasma of patients with familial HDL-deficiency.Z Gastroenterol.34 (Suppl.) 3:143–144.

Mahley, R.W. and Huang, Y (1999) Apolipoprotein E: From atherosclerosis to Alzheimerís disease and beyond.Curr. Opin. Lipidol.10:207–217.

Mahley, R.W., Huang, Y., and Rall, S.C. (1999) Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): Questions, quandaries, and paradoxes. J. Lipid Res.40:1933–1949.

Huang Y, Weisgraber KH, Mucke L, and Mahley RW. (2003) Apolipoprotein E: Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimerís disease. J. Mol. Neurosci. 23:187–202.

Raber J, Huang Y, and Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging. 25:641–660.

Huang Y (2006) Apolipoprotein E and Alzheimer’s Disease. Neurology 24:S79–85.

Xu Q and Huang Y (2006) Lipid metabolism and neurodegenerative disorders. Future Lipidology. 1:441–453.

Mahley RW and Huang Y (2006) Apolipoprotein (apo) E4 and Alzheimer’s disease: Unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurol Scand Suppl. 185:8–14.

Huang Y (2006) Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr. Opin. Drug Discov. Developm. 9:627–641.

Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, and Mahley RW (2007) Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease.) Pharmacogenomics J. 7:10–28.

Mahley RW, Huang Y, Weisgraber KH (2007) Detrimental effects of apolipoprotein E4: Potential therapeutic targets in Alzheimer’s disease. Curr. Alzheimer Res. 4:537–40.

Mahley RW, Weisgraber KH, and Huang Y (2009) Apolipoprotein E: Structure determines function from altherosclerosis to Alzheimer’s disease to AIDS. J. Lipid Res. 50:S183–S188.

Mahley RW and Huang Y (2009) Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Annals of Neurology. 65:623–625.

Huang Y (2010) Ab-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease Trends Mol. Med. 16:287–294.

Huang Y (2010) Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr. Opin. Lipidol. 21:337–345.

Huang Y (2011) Roles of apolipoprotein E4 (apoE4) in the pathogenesis of Alzheimer’s disease: lesions from apoE mouse models. Biochem. Soc. Trans. 39:924–932.

Huang Y and Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222.

Mahley RW and Huang Y (2012) Small-molecule structure correctors target abnormal protein structure and function: the structure corrector rescue of apoE4–associated neuropathology. J. Med. Chem. in press.

Review Articles Published in Proceedings
Assmann, G., von Eckardstein, A., Huang, Y., and Wu, S. (1995) A lipoprotein present in normal and HDL-deficient plasmas releases cholesterol from cells.Atherosclerosis X, Woodford, F.P. Editor. p. 662–665.

von Eckardstein, A., Huang, Y., and Assmann, G. (1996) Role of high density lipoprotein subclasses in reverse cholesterol transport. Proceedings of the Symposium on HDL-Deficiency and Atherosclerosis. Kluver Verlag, p. 17–23.

von Eckardstein, A., Huang, Y., Wu, S., and Assmann, G. (1996) Role of apoE for reverse cholesterol transport. Proceedings of the C.B.Pennington Conference on Nutrition, Genetics, and Heart Disease. Baton Rouge, Louisiana, USA. p. 189.

Abstracts Published in Journals
von Eckardstein, A., Huang, Y., Wu, S., Maeda, N., and Assmann, G. (1993) A soly apolipoprotein E containing plasma lipoprotein with electrophoretic gamma-mobility takes up cellular cholesterol. Circulation 88 (Suppl. ) I–269.

von Eckardstein, A., Huang, Y., Wu, S., Noseda, G., and Assmann, G. (1994) Uptake, transfer, and esterification of cell-derived cholesterol in plasma of patients with familial HDL-deficiency. Atherosclerosis 109:232.

Huang, Y., von Eckardstein, A., Wu, S. and Assmann, G. (1994) Generation and conversion of preb1-LpA-I in vitro: Evidence for the presence in human plasma of a factor converting preb1-LpA-I into a-LpA-I. Xth International Symposium on Atherosclerosis. Atherosclerosis 109:232.

Assmann, G., Huang, Y., Wu, S., and von Eckardstein, A. (1994) A lipoprotein containing only apoE present in normal and HDL-deficient plasmas releases cholesterol from cells. Atherosclerosis109:334.

von Eckardstein, A., Huang, Y., Raabe, M., Langer, C., Wu, S., Seedorf, Udo., Maeda, N., and Assmann, G. (1995) Reverse cholesterol transport in normal, apolipoprotein A-I, and apolipoprotein E-deficient mice. Circulation 92 (Suppl.):I–557

von Eckardstein, A., Huang, Y., Steinmetz, A., and Assmann, G. (1995) Apolipoprotein A-IV containing high density lipoproteins take up and esterify cell derived cholesterol in plasma. Circulation 92 (Suppl.):I–557

Huang, Y., Schwendner, S.W., Rall, S.C., and Mahley, R.W. (1996) Type III hyperlipoproteinemic transgenic rabbits with defective human apolipoprotein E. Circulation 94 (Suppl. ) I–518

Huang, Y., Liu, X.Q., Rall, S.C., and Mahley, R.W. (1997) Hypo-low density lipoprotein cholesterol effect of apolipoprotein E2 in transgenic mice is caused by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. Circulation 96 (Suppl.) I–39.

Huang, Y., Brecht, W.J., Liu, X.Q., Rall, S.C., and Mahley, R.W. (1999) Apolipoprotein E promoter —219T/G polymorphism: A powerful predictor of plasma lipid levels in humans. Circulation100 (Suppl.) I–197.

Huang, Y., Brecht, W.J., Liu, X.Q., Rall, S.C., and Mahley, R.W. (1999) Overexpression of apolipoprotein E stimulates synthesis and mobilization of triglycerides to the endoplasmic reticulum in rat hepatoma cells (McA-RH7777). Circulation 100: I–686.

Huang, Y., Liu, X.Q., Rall, S.C., and Mahley, R.W. (2000) Pathogenesis of type III hyperlipoproteinemia: Lessons from transgenic animal studies. Atherosclerosis 150 (Suppl.1) S6.

Huang, Y., Brecht, W.J., Liu, X.Q., Wang, Y., Taylor, J.M., Rall, S.C., and Mahley, R.W. (2000) Apolipoprotein (apo) E modulates hepatic very low density lipoprotein (VLDL) assembly and secretion. Atherosclerosis 151(1):158

>Huang, Y., Liu, X.Q., and Mahley, R.W. (2000) Differential effects of cytosolic apolipoprotein (apo) E3 and apoE4 on neurite outgrowth and the cytoskeleton. Neurobiology of Aging 21(1S):S216.